|
|
|
|
|
PUTRAJAYA, Malaysia, May 21, 2022 - (ACN Newswire) - Straumann Group Sdn. Bhd, the Malaysian subsidiary of Straumann Group, global leader in implantology and aesthetic-dentistry, (Straumann Malaysia) intends to provide 3,000 dental implant packages worth in excess of RM10 million, which will benefit the lower-income group (B40) and underprivileged Malaysians. This intention was communicated within the Memorandum of Understanding (MoU) announced by the Ministry of Health Malaysia (MOH).
 | | Mr. Guillaume Daniellot, CEO of Straumann Group; Yang Berhormat Tuan Khairy Jamaluddin, Minister of Health Malaysia [L-R] |
The discussion of the MoU was led by Malaysia's Minister of Health, Yang Berhormat Tuan Khairy Jamaluddin and the Straumann Group's Chief Executive Officer, Guillaume Daniellot.
Straumann Group's Chief Executive Officer, Guillaume Daniellot said, "This is a significant milestone for the Straumann Group, and we appreciate MOH's willingness to collaborate with us. Oral, especially dental health is critical to everyone's wellbeing, and we believe that everyone has the right to quality medical treatments, especially holistic and ethical dental treatments. This Programme is part of the broader community oral health initiative to raise awareness on the long-term impact of tooth loss while ensuring that underprivileged Malaysian communities have access to world-class dental products and services for a better quality of life. We look forward to working closely with our local counterparts to bring the Programme to life while supporting MOH in its ambitions under the National Oral Health Plan 2021-2030."
About Straumann Group
The Straumann Group (SIX: STMN) is a global leader in tooth replacement and orthodontic solutions that restore smiles and confidence. It unites global and international brands that stand for excellence, innovation and quality in replacement, corrective and digital dentistry, including Anthogyr, ClearCorrect, Dental Wings, Medentika, Neodent, NUVO, Straumann and other fully/partly owned companies and partners. In collaboration with leading clinics, institutes and universities, the Group researches, develops, manufactures and supplies dental implants, instruments, CADCAM prosthetics, orthodontic aligners, biomaterials and digital solutions for use in tooth correction, replacement and restoration or to prevent tooth loss.
Headquartered in Basel, Switzerland, the Group currently employs more than 9000 people worldwide. Its products, solutions and services are available in more than 100 countries through a broad network of distribution subsidiaries and partners. For more information, please visit our website at: https://www.straumann.com
Media Contacts:
Lok Ru Jun
Narro Communications
E: rujun@narrocomms.com
T: +6012 339 0613
Cheong Sue Fyenn
Narro Communications
E: suefyenn@narrocomms.com
T: +6016 910 7625
Topic: Press release summary
Source: Straumann Group
Sectors: Healthcare & Pharm, Local Biz
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
Latest Press Releases
Doubleview Gold Clarifies Preliminary Economic Assessment Results for the Hat Project; Updated Scenario B NPV Increased to C$7.27 Billion
Mar 24, 2026 04:59 HKT/SGT
|
|
|
OMP Positioned Highest for Both Completeness of Vision and Ability to Execute in the 2026 Gartner(R) Magic Quadrant(TM) for Supply Chain Planning Solutions: Process Industries
Mar 23, 2026 23:15 HKT/SGT
|
|
|
Wellgistics Health Inc. Signs $105,000,000 Letter of Intent to Evaluate Potential Acquisition of Neuritek Therapeutics, Inc. which is Pioneering Innovative Therapies for Neurological and Psychiatric Disorders
Mar 23, 2026 21:05 HKT/SGT
|
|
|
Essex Bio-Technology Reports Robust Results for FY2025, Turnover Soars 8.6% to HK$1814 million, Net Profit up 3.5% to HK$ 318.1 million, Total Dividend Increases by 16.7% to HK14 Cents per Share
Mar 23, 2026 20:51 HKT/SGT
|
|
|
GMG Launches European Sales Team; G(R) Lubricant Patent Accepted for Europe
Mar 23, 2026 20:29 HKT/SGT
|
|
|
Everest Medicines Enters into Asset Purchase Agreement for Etripamil Nasal Spray, Expanding Cardiovascular Footprint
Mar 23, 2026 18:59 HKT/SGT
|
|
|
From SGD to Global Spending: How Singaporeans Can Avoid FX Fees While Travelling Overseas
Mar 23, 2026 14:15 HKT/SGT
|
|
|
Fujitsu-developed traffic simulation system utilized in Maebashi City's public transportation planning
Monday, March 23, 2026 1:24:00 PM
|
|
|
Hitachi Receives the 2026 Catalyst Award, a Global Recognition for Building an Inclusive Organization
Monday, March 23, 2026 10:49:00 AM
|
|
|
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026
Monday, March 23, 2026 10:19:00 AM
|
|
|
|
|
More Press release >> |
|
 |
|
|
|
|
 |
|
